Study in a Sentence: Researchers used affinity-purification mass spectrometry (AP-MS) to identify interactions between SARS-CoV-2 proteins and human proteins, which yielded 66 druggable proteins that are targeted by 69 existing FDA-approved drugs, drugs in clinical trials, and/or preclinical compounds.
Healthy for Humans: This proteomic analysis presents drugs and compounds that may perturb the way SARS-CoV-2 interacts with human cells. By testing these compounds in human cells for disruptions in SARS-CoV-2 activity, researchers can get a glimpse of their therapeutic value in preventing COVID-19.
Redefining Research: With no antiviral drugs or vaccines currently available for the novel coronavirus SARS-CoV-2, there is a need for clues about the molecular mechanisms and substrates of its infection in human cells. Using a combination of a systematic proteomic analysis and a chemoinformatic drug search, researchers were able to identify both biological processes affected by SARS-CoV2 infection and potential therapeutic compounds.